May 14, 1997 |
Ovarian cancer, one of the most deadly forms of the disease, has been fought successfully with an experimental three-drug therapy applied after surgery, researchers said. Based on 60 patients given the three-drug cocktail, 70% were disease-free 22 months after surgery, said Eddie Reed of the National Cancer Institute in Bethesda, Md. By comparison, previous data showed about half of women who received standard chemotherapy after optimal surgery were disease-free after 18 to 19 months.
June 9, 1999 |
Alza Corp.'s Doxil chemotherapy drug should be approved for expanded use as a treatment for ovarian cancer, the advisory panel for the Food and Drug Administration said. Doxil was cleared in the U.S. in 1995 for treating Kaposi's sarcoma, a cancer most often associated with AIDS.
March 21, 2001 |
Taking estrogen for 10 years or more after menopause doubled women's risk of fatal ovarian cancer, says a new study that adds to the confusion facing millions of Americans debating whether to use the hormone. Estrogen users shouldn't panic: Ovarian cancer is rare enough that few estrogen users died despite the increased risk, especially compared to bigger killers, such as heart disease, that estrogen might help, experts cautioned. Also, most of the women studied used estrogen alone.
December 30, 1992 |
The Food and Drug Administration on Tuesday approved the use of the drug taxol for the treatment of advanced ovarian cancer, while researchers held out hope that it might eventually be effective in earlier stages of the disease and against other kinds of cancers. Health officials cautioned, however, that while studies show the drug can prolong life for some ovarian cancer patients, taxol is not considered a cure.
December 26, 1991 |
Ovarian cancer has recently been thrust into the limelight. First came comedian Gilda Radner's illness and death in 1989. Then "thirtysomething" character Nancy Weston endured a two-year prime-time battle with the disease. The attendant publicity has increased our awareness of ovarian cancer--and spawned confusion over just how women should respond to the threat.
May 1, 1990 |
When British researchers reported recently on a new method for early detection of ovarian cancer, gynecologists' offices were flooded with telephone calls. Women wanted to know where they could get the special ultrasound test. Consciousness about ovarian cancer is at an all-time high, thanks partly to "thirtysomething's" television dramatization of Nancy Weston's battle with the disease and to the 1989 death of actress Gilda Radner.
March 26, 2001 |
Women who take the hormone estrogen for 10 years or more after menopause substantially increase their risk of dying of ovarian cancer compared with women who do not take the hormone, according to a study released Tuesday. In the American Cancer Society study of more than 211,000 post-menopausal women, those with any history of using hormone replacement therapy had a somewhat higher death rate from ovarian cancer than nonusers.
CALIFORNIA | LOCAL
November 7, 1996 |
Doctors have found one small bit of good news for women who inherit a genetic susceptibility to ovarian cancer: Their form of the disease is less aggressive than that in women who do not have a genetic susceptibility but still get ovarian cancer. Women who are born with this tendency, which results from a flaw in a gene called BRCA1, face about a 65% lifetime risk of getting ovarian cancer and an 85% risk of breast cancer. There is a 95% risk they will get one or the other. Dr. Stephen C.
September 18, 2000 |
Ovarian cancer has long been among the most feared diseases among women. And rightly so. It's often detected in a late stage. And the disease is very hard to cure once it has spread beyond the ovaries. An estimated 23,100 U.S. women will be diagnosed with the disease this year and about 14,000 will die, according to the Ovarian Cancer National Alliance.
March 12, 2001 |
Aspirin's potential as an ovarian cancer preventive gained support last week, with yet another study suggesting it may reduce a woman's risk of the deadly disease. The findings, while limited in scope, are generating excitement because currently only oral contraceptives are known to reduce risk. Such research is particularly important because ovarian cancer produces vague symptoms, often leading to a diagnosis when the cancer is already advanced. Each year, about 23,000 U.S.